Advanced

Smoking at onset of rheumatoid arthritis (RA) and its effect on disease activity and functional status: experiences from BARFOT, a long-term observational study on early RA

Soderlin, M. K.; Petersson, Ingemar LU ; Bergman, S. and Svensson, B (2011) In Scandinavian Journal of Rheumatology 40(4). p.249-255
Abstract
Objectives: To assess the effects of smoking on disease outcome in a large cohort of patients with early rheumatoid arthritis (RA). Methods: Between 1996 and 2004, 1787 adult patients (disease duration <= 1 year) were included in the BARFOT early RA study in Sweden. Smoking status was recorded at inclusion in the study. Disease Activity Score using 28 joint counts (DAS28), C-reactive protein (CRP), Health Assessment Questionnaire (HAQ) score, rheumatoid factor (RF), antibodies to cyclic citrullinated peptide (anti-CCP), general health (GH) and pain visual analogue scales (VAS), and drug treatment were registered at inclusion and at follow-up at 3, 6, and 12 months. European League Against Rheumatism (EULAR) response and remission... (More)
Objectives: To assess the effects of smoking on disease outcome in a large cohort of patients with early rheumatoid arthritis (RA). Methods: Between 1996 and 2004, 1787 adult patients (disease duration <= 1 year) were included in the BARFOT early RA study in Sweden. Smoking status was recorded at inclusion in the study. Disease Activity Score using 28 joint counts (DAS28), C-reactive protein (CRP), Health Assessment Questionnaire (HAQ) score, rheumatoid factor (RF), antibodies to cyclic citrullinated peptide (anti-CCP), general health (GH) and pain visual analogue scales (VAS), and drug treatment were registered at inclusion and at follow-up at 3, 6, and 12 months. European League Against Rheumatism (EULAR) response and remission criteria were applied at 3, 6, and 12 months. Results: The proportion of patients who smoked at inclusion in the study fell from 29% in 1996 to 20% in 2004. There were no significant differences in disease activity at inclusion stratified according to smoking status. At 12 months of follow-up, 18% of current smokers at inclusion, 12% of previous smokers, and 11% of never smokers had high disease activity (DAS28 > 5.1, p = 0.005). Significantly fewer current smokers were in remission at 12 months (33%) compared to never smokers (36%) and previous smokers (42%) (p = 0.013). Current smoking at inclusion independently predicted poor EULAR response up to 12 months of follow-up. Conclusion: The present study gives some support to earlier data indicating that RA patients who smoke have a more active disease but further studies are needed to confirm this. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Scandinavian Journal of Rheumatology
volume
40
issue
4
pages
249 - 255
publisher
Taylor & Francis
external identifiers
  • wos:000294068000001
  • scopus:80051960880
ISSN
1502-7732
DOI
10.3109/03009742.2010.541495
language
English
LU publication?
yes
id
d07a7e39-17d5-40c0-a033-1004b2d40938 (old id 2160977)
date added to LUP
2011-10-03 08:31:21
date last changed
2017-01-01 04:09:22
@article{d07a7e39-17d5-40c0-a033-1004b2d40938,
  abstract     = {Objectives: To assess the effects of smoking on disease outcome in a large cohort of patients with early rheumatoid arthritis (RA). Methods: Between 1996 and 2004, 1787 adult patients (disease duration &lt;= 1 year) were included in the BARFOT early RA study in Sweden. Smoking status was recorded at inclusion in the study. Disease Activity Score using 28 joint counts (DAS28), C-reactive protein (CRP), Health Assessment Questionnaire (HAQ) score, rheumatoid factor (RF), antibodies to cyclic citrullinated peptide (anti-CCP), general health (GH) and pain visual analogue scales (VAS), and drug treatment were registered at inclusion and at follow-up at 3, 6, and 12 months. European League Against Rheumatism (EULAR) response and remission criteria were applied at 3, 6, and 12 months. Results: The proportion of patients who smoked at inclusion in the study fell from 29% in 1996 to 20% in 2004. There were no significant differences in disease activity at inclusion stratified according to smoking status. At 12 months of follow-up, 18% of current smokers at inclusion, 12% of previous smokers, and 11% of never smokers had high disease activity (DAS28 &gt; 5.1, p = 0.005). Significantly fewer current smokers were in remission at 12 months (33%) compared to never smokers (36%) and previous smokers (42%) (p = 0.013). Current smoking at inclusion independently predicted poor EULAR response up to 12 months of follow-up. Conclusion: The present study gives some support to earlier data indicating that RA patients who smoke have a more active disease but further studies are needed to confirm this.},
  author       = {Soderlin, M. K. and Petersson, Ingemar and Bergman, S. and Svensson, B},
  issn         = {1502-7732},
  language     = {eng},
  number       = {4},
  pages        = {249--255},
  publisher    = {Taylor & Francis},
  series       = {Scandinavian Journal of Rheumatology},
  title        = {Smoking at onset of rheumatoid arthritis (RA) and its effect on disease activity and functional status: experiences from BARFOT, a long-term observational study on early RA},
  url          = {http://dx.doi.org/10.3109/03009742.2010.541495},
  volume       = {40},
  year         = {2011},
}